Nivolumab, an immunoglobulin monoclonal antibody, specifically targets programmed cell death protein 1 (PD-1) receptors to block pathways cancer cells use to evade immune surveillance by cytotoxic T cells [2]. This evidence concerns the gene PDCD1 and cancer.